Invex Therapeutics (ASX:IXC) 3-Year Share Buyback Ratio : -3.60% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Invex Therapeutics's current 3-Year Share Buyback Ratio was -3.60%.

The historical rank and industry rank for Invex Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:

ASX:IXC' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -3.6 Med: -3.6 Max: -3.6
Current: -3.6

During the past 5 years, Invex Therapeutics's highest 3-Year Share Buyback Ratio was -3.60%. The lowest was -3.60%. And the median was -3.60%.

ASX:IXC's 3-Year Share Buyback Ratio is ranked better than
73.02% of 1286 companies
in the Biotechnology industry
Industry Median: -10.35 vs ASX:IXC: -3.60

Competitive Comparison of Invex Therapeutics's 3-Year Share Buyback Ratio

For the Biotechnology subindustry, Invex Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's 3-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Invex Therapeutics (ASX:IXC) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Invex Therapeutics 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.